Long-Term Survival after Gemcitabine and Cisplatin in Patients with Locally Advanced Transitional Cell Carcinoma of the Bladder: Focus on Supplementary Treatment Strategies

European Urology

Volumn 52, Issue 2, 2007, Pages 478-487

  Als, Anne Birgitte ^a   Sengelov, Lisa ^b   von der Maase, Hans ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Bladder cancer; Cisplatin; Combination chemotherapy; Gemcitabine; Locally advanced; Radiotherapy; Surgery; Surveillance

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CYSTECTOMY; DRUG EFFICACY; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHI-SQUARE DISTRIBUTION; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 34250729132     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.03.016     Document Type: Article

References (16)

1. Landis S.H., Murray T., Bolden S., et al. A. Cancer statistics, 1999. CA Cancer J Clin 49 (1999) 8-31
2. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
3. Sengelov L., Kamby C., Schou G., et al. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer 74 (1994) 123-133
4. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17 (1999) 3173-3181
5. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068-3077
6. Dodd P.M., McCaffrey J.A., Herr H., et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17 (1999) 2546-2552
7. Herr H.W., Donat S.M., and Bajorin D.F. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 165 (2001) 811-814
8. Fossa S.D., Sternberg C., Scher H.I., et al. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer 74 (1996) 1655-1659
9. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.
10. Fokdal L., Hoyer M., and von der Maase H. Radical radiotherapy for urinary bladder cancer: treatment outcomes. Expert Rev Anticancer Ther 6 (2006) 269-279
11. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64 (1989) 2448-2458
12. Sengelov L., Kamby C., Geertsen P., et al. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother Pharmacol 46 (2000) 357-364
13. Konety B.R., Allareddy V., and Herr H. Complications after radical cystectomy: analysis of population-based data. Urology 68 (2006) 58-64
14. Fokdal L., Hoyer M., Meldgaard P., et al. Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. Radiother Oncol 72 (2004) 139-145
15. Nieuwenhuijzen J.A., Bex A., Meinhardt W., et al. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol 174 (2005) 80-85
16. Shelley MD, Barber J, Wilt T, et al. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002:CD002079.